UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 272

Sortiert nach

Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients

Annals of oncology, 2014-10, Vol.25 (10), p.2030-2035

2014

Volltextzugriff (PDF)

Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma

Clinical radiology, 2017-10, Vol.72 (10), p.850-857

2017

Volltextzugriff (PDF)

Cyclophosphamide as a first-line therapy in LGL leukemia

Leukemia, 2014-05, Vol.28 (5), p.1134-1136

2014

Volltextzugriff (PDF)

Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia

Leukemia, 2017-02, Vol.31 (2), p.292-300

2017

Volltextzugriff (PDF)

Long-term effect of rituximab in anti-mag polyneuropathy

Neurology, 2008-11, Vol.71 (21), p.1742

2008

Volltextzugriff (PDF)

Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells

Leukemia, 2011-11, Vol.25 (11), p.1768-1781

2011

Volltextzugriff (PDF)

P27 HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE

HemaSphere, 2023-05, Vol.7 (S2), p.25-25

2023

Volltextzugriff (PDF)

CLINICAL AND BIOLOGICAL PREDICTORS OF OUTCOME IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA: A SINGLE CENTER EXPERIENCE OF 205 PATIENTS

Hematological oncology, 2019-06, Vol.37 (S2), p.288-289

2019

Volltextzugriff (PDF)

Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2

Leukemia, 2014-10, Vol.28 (10), p.2094-2097

2014

Volltextzugriff (PDF)

P600: HIGH‐DEPTH RNA‐SEQUENCING IDENTIFIES CD8+ STAT3 MUTATED T‐LGLL PATIENTS AS A DISTINCT BIOLOGICAL ENTITY WITHIN THE DISEASE HETEROGENEITY

HemaSphere, 2022-06, Vol.6, p.499-500

2022

Volltextzugriff (PDF)

P605: T‐CELL PROLYMPHOCYTIC LEUKEMIA: MOLECULAR CHARACTERIZATION OF A COHORT OF 18 PATIENTS AND EVALUATION OF BORTEZOMIB AS A POSSIBLE THERAPEUTIC STRATEGY

HemaSphere, 2022-06, Vol.6, p.504-505

2022

Volltextzugriff (PDF)

P1279: INHIBITION OF PROTEIN KINASE CK2 AND BCL‐2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH

HemaSphere, 2022-06, Vol.6 (Suppl), p.1164-1165

2022

Volltextzugriff (PDF)

State of the art in natural killer cell malignancies

International journal of laboratory hematology, 2012-04, Vol.34 (2), p.117-128

2012

Volltextzugriff (PDF)

P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS

HemaSphere, 2022-04, Vol.6 (Suppl), p.11-12

2022

Volltextzugriff (PDF)

Incidence, Risk Factors, Impact of Infections on Outcome of MDS, CMML and AML Patients Treated with Azacitidine: Single Centre Experience

Leukemia research, 2017-04, Vol.55, p.S59-S61

2017

Volltextzugriff (PDF)

Expansion of Bone Marrow NK Lymphocytes is Associated with Higher Probability of Response to Azacitidine Treatment and Survival Benefit

Leukemia research, 2017-04, Vol.55, p.S130-S130

2017

Volltextzugriff (PDF)

MIR146‐B expression levels correlate with biological and clinical features in T‐LGL leukemia

Hematological oncology, 2017-06, Vol.35 (S2), p.285-285

2017

Volltextzugriff (PDF)

LONG‐TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT)

Hematological oncology, 2019-06, Vol.37 (S2), p.256-257

2019

Volltextzugriff (PDF)

Clinical spectrum of γδ+ T cell LGL leukemia: Analysis of 20 cases

Leukemia research, 2008-01, Vol.32 (1), p.45-48

2008

Volltextzugriff (PDF)

93 INFECTIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE: RETROSPECTIVE ANALYSIS FROM A SINGLE CENTER

Leukemia research, 2015-04, Vol.39, p.S47-S47

2015

Volltextzugriff (PDF)

Rituximab-responsive CIDP

European journal of neurology, 2004-11, Vol.11 (11), p.788-788

2004

Volltextzugriff (PDF)

1 – 25 von 272

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(246)
Mit Volltextzugriff
(225)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(175)
Science & Technology
(146)
Life Sciences & Biomedicine
(144)
Male
(128)
Female
(124)
Biological And Medical Sciences
(118)
Medical Sciences
(112)
Adult
(104)
Middle Aged
(85)
Hematology
(63)
Hematologic And Hematopoietic Diseases
(60)
Aged
(56)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(54)
Immunology
(36)
Aids/hiv
(33)
Oncology
(33)
Killer Cells, Natural - Immunology
(31)
Cytotoxicity, Immunologic
(26)
Phenotype
(25)
Immunophenotyping
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients

Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma

Cyclophosphamide as a first-line therapy in LGL leukemia

Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia

Long-term effect of rituximab in anti-mag polyneuropathy

Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells

P27 HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE

CLINICAL AND BIOLOGICAL PREDICTORS OF OUTCOME IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA: A SINGLE CENTER EXPERIENCE OF 205 PATIENTS

Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2

P600: HIGH‐DEPTH RNA‐SEQUENCING IDENTIFIES CD8+ STAT3 MUTATED T‐LGLL PATIENTS AS A DISTINCT BIOLOGICAL ENTITY WITHIN THE DISEASE HETEROGENEITY

P605: T‐CELL PROLYMPHOCYTIC LEUKEMIA: MOLECULAR CHARACTERIZATION OF A COHORT OF 18 PATIENTS AND EVALUATION OF BORTEZOMIB AS A POSSIBLE THERAPEUTIC STRATEGY

P1279: INHIBITION OF PROTEIN KINASE CK2 AND BCL‐2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH

State of the art in natural killer cell malignancies

P49 A REAL‐WORLD RETROSPECTIVE‐PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE

P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI‐CD38 MONOCLONAL ANTIBODY: A RETRO‐PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS

P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL‐LIFE STUDY INCLUDING 389 PATIENTS

P07 BORTEZOMIB‐MELPHALAN‐PREDNISONE (VMP) VS. LENALIDOMIDE‐DEXAMETHASONE (RD) IN REAL‐LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL

Incidence, Risk Factors, Impact of Infections on Outcome of MDS, CMML and AML Patients Treated with Azacitidine: Single Centre Experience

Expansion of Bone Marrow NK Lymphocytes is Associated with Higher Probability of Response to Azacitidine Treatment and Survival Benefit

MIR146‐B expression levels correlate with biological and clinical features in T‐LGL leukemia

LONG‐TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT)

Clinical spectrum of γδ+ T cell LGL leukemia: Analysis of 20 cases

93 INFECTIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE: RETROSPECTIVE ANALYSIS FROM A SINGLE CENTER

Rituximab-responsive CIDP

Suchergebnisse filtern